茶多酚对小鼠细胞色素P450和b_5含量及CYP2E1和CYP1A2表达的影响
|
摘要
目的:研究短期内应用茶多酚(tea polyphenols, TPs)对小鼠细胞色素P450 (CYP450)和b5含量及CYP2E1和CYP1A2表达的影响。
方法:1.测定CYP450和b_5含量:雄性小鼠分别按小剂量(25 mg/kg﹒d~-)、中剂量(50 mg/kg﹒d~-)和高剂量(100 mg/kg﹒d~-)TPs腹腔注射给药两天。氯霉素为阳性对照组,在取肝前1小时以50 mg/kg﹒d~-腹腔注射给药;阴性对照组给等量生理盐水,在第三天所有小鼠断头处死取肝,制备肝微粒体,用紫外分光光度计测定小鼠肝脏CYP450和b5含量。2. TPs对扑热息痛所致小鼠死亡率的影响:雄性小鼠分别按100 mg/kg﹒d~-、200 mg/kg﹒d~-和400 mg/kg﹒d~- TPs灌胃给药6天。阳性对照组给予900 mg/kg的N-乙酰半胱氨酸,阴性对照组给予等量的生理盐水。末次给药后1小时,所有小鼠灌胃扑热息痛1000 mg/kg,记录72小时内各组小鼠的死亡数量并计算出药物的保护率。3. TPs对CYP2E1和CYP1A2表达的影响:雄性小鼠分别按100 mg/kg﹒d~-、200 mg/kg﹒d~-和400 mg/kg﹒d~- TPs灌胃给药5天。阳性对照组和阴性对照组分别给予等量的生理盐水。末次给药后1小时,除生理盐水组外,所有小鼠灌胃扑热息痛500 mg/kg,24小时后断头处死立即取肝,用冷的生理盐水冲洗,把部分肝脏标本放于10%福尔马林固定和-80℃中冻存。用病理切片观察肝脏病变,用免疫组化、Western blot和RT-PCR方法检测CYP2E1和CYP1A2表达情况。
结果:与阴性对照组相比,TPs三个剂量组小鼠CYP450和b_5含量明显降低,差异显著(P<0.01),且有剂量依赖性;TPs能显著降低扑热息痛所致小鼠的死亡率和改善扑热息痛所致肝损伤病理改变;与阴性对照组相比,TPs中剂量组和低剂量组能显著降低CYP2E1蛋白和mRNA表达(P<0.01),而TPs各剂量组能显著降低CYP1A2蛋白和mRNA表达(P<0.05)。
结论:
1.短期应用TPs对CYP450和b5有抑制作用并呈剂量依赖性。
2.在扑热息痛诱发的小鼠肝损伤模型中,TPs显示了显著的肝脏保护作用,表现为小鼠的死亡率明显降低和肝脏病变明显改善。
3.在扑热息痛诱发的小鼠肝损伤模型中,TPs对CYP450同功酶CYP2E1和CYP1A2蛋白和mRNA表达有显著抑制作用且有剂量依赖性,这一结果提示TPs通过抑制CYP2E1和CYP1A2基因转录,使扑热息痛代谢降低,毒性产物N-乙酰-P-苯醌亚胺生成减少,这可能是TPs对扑热息痛肝损伤保护作用的机制之一。
Objective: To investigate the effect of tea ployphenols (TPs) on the level of hepatic cytochrome P450 (CYP450) and b_5 along with the expression of CYP2E1 and CYP1A2 in mice after short time taking TPs.
Methods: 1. Kunming male mice were intraperitoneally injected with TPs at the doses of 25, 50 and 100 mg/ kg﹒d~- for two days. The positive control group was given chloramphenicol at the dose of 50 mg/kg﹒d~- 1h before killing the mice. The negative control group was given the same volume of saline solution. After the mice were killed by decapitation, The livers were removed and microsomes were isolated and then, the contents of CYP450 and b5 were measured by UV-spectrophotometry and compared with control group mice. 2. To evaluate the detoxification effect of TPs, the male mice were intragastricly pre-treated with TPs at the doses of 100, 200 and 400 mg/ kg﹒d~- for six days, The positive control group was given N-Broncholysin at the dose of 900 mg/kg﹒d~-. The negative control group was given the same volume of saline solution and then, all the mice were given paracetamol at the dose of 1000 mg/kg. The acute mortality was compared with control mice. 3. To examine the expression of CYP2E1 and CYP1A2, male mice were pre-treated with TPs (100, 200, and 400 mg/kg﹒d~-) for five days. The model group and the negative control group were given the same volume of saline solution. Then the mice were given paracetamol at the dose of 500 mg/kg 1 hour later after the last time TPs administration except the mice in negative control group. The livers were removed immediately and washed with cold saline solution .Then all specimens were fixed in formalin for histological examinations or snap-frozen in liquid nitrogen and stored at -80℃for protein and RNA extraction. CYP2E1 and CYP1A2 protein and mRNA expression levels in the liver were evaluated by western blotting, immunohistochemical staining and RT-PCR.
Results: The contents of CYP450 and b5 in the livers of mice in three TPs-treated groups were dose-dependently decreased compared with the negative control mice (P<0.01) after short time taking TPs. TPs treatment significantly improved hepatic lesions and led to a dramatic reduction of the mortality of paracetamol-treated mice. TPs treatment resulted in a significant reduction of the CYP2E1 and CYP1A2 expression at both protein and mRNA levels in a dose-dependent manner (P<0.01).
Conclusions:
1. TPs could suppress both CYP450 and b5 in a dose dependent manner after short time administration.
2. In the paracetamol induced mouse liver injury model, TPs demonstrated obvious hepato-protective effects dose-dependently which were shown by substantially lowering the mortality of mice and obviously improving hepatic lesions.
3. In the paracetamol induced mouse liver injury model, TPs could supressed CYP450 isoform CYP2E1 and CYP1A2 expression to defend paracetamol-induced liver damage. This result suggested TPs could reduced paracetamol’s metabolism and decrease the production of the hepatotoxic N-acetyl-p-benzoquinonimine by suppressing genetic transcription of CYP2E1 and CYP1A2. This might be one of the mechanisms to hepato-protective effects of TPs.
方法:1.测定CYP450和b_5含量:雄性小鼠分别按小剂量(25 mg/kg﹒d~-)、中剂量(50 mg/kg﹒d~-)和高剂量(100 mg/kg﹒d~-)TPs腹腔注射给药两天。氯霉素为阳性对照组,在取肝前1小时以50 mg/kg﹒d~-腹腔注射给药;阴性对照组给等量生理盐水,在第三天所有小鼠断头处死取肝,制备肝微粒体,用紫外分光光度计测定小鼠肝脏CYP450和b5含量。2. TPs对扑热息痛所致小鼠死亡率的影响:雄性小鼠分别按100 mg/kg﹒d~-、200 mg/kg﹒d~-和400 mg/kg﹒d~- TPs灌胃给药6天。阳性对照组给予900 mg/kg的N-乙酰半胱氨酸,阴性对照组给予等量的生理盐水。末次给药后1小时,所有小鼠灌胃扑热息痛1000 mg/kg,记录72小时内各组小鼠的死亡数量并计算出药物的保护率。3. TPs对CYP2E1和CYP1A2表达的影响:雄性小鼠分别按100 mg/kg﹒d~-、200 mg/kg﹒d~-和400 mg/kg﹒d~- TPs灌胃给药5天。阳性对照组和阴性对照组分别给予等量的生理盐水。末次给药后1小时,除生理盐水组外,所有小鼠灌胃扑热息痛500 mg/kg,24小时后断头处死立即取肝,用冷的生理盐水冲洗,把部分肝脏标本放于10%福尔马林固定和-80℃中冻存。用病理切片观察肝脏病变,用免疫组化、Western blot和RT-PCR方法检测CYP2E1和CYP1A2表达情况。
结果:与阴性对照组相比,TPs三个剂量组小鼠CYP450和b_5含量明显降低,差异显著(P<0.01),且有剂量依赖性;TPs能显著降低扑热息痛所致小鼠的死亡率和改善扑热息痛所致肝损伤病理改变;与阴性对照组相比,TPs中剂量组和低剂量组能显著降低CYP2E1蛋白和mRNA表达(P<0.01),而TPs各剂量组能显著降低CYP1A2蛋白和mRNA表达(P<0.05)。
结论:
1.短期应用TPs对CYP450和b5有抑制作用并呈剂量依赖性。
2.在扑热息痛诱发的小鼠肝损伤模型中,TPs显示了显著的肝脏保护作用,表现为小鼠的死亡率明显降低和肝脏病变明显改善。
3.在扑热息痛诱发的小鼠肝损伤模型中,TPs对CYP450同功酶CYP2E1和CYP1A2蛋白和mRNA表达有显著抑制作用且有剂量依赖性,这一结果提示TPs通过抑制CYP2E1和CYP1A2基因转录,使扑热息痛代谢降低,毒性产物N-乙酰-P-苯醌亚胺生成减少,这可能是TPs对扑热息痛肝损伤保护作用的机制之一。
Objective: To investigate the effect of tea ployphenols (TPs) on the level of hepatic cytochrome P450 (CYP450) and b_5 along with the expression of CYP2E1 and CYP1A2 in mice after short time taking TPs.
Methods: 1. Kunming male mice were intraperitoneally injected with TPs at the doses of 25, 50 and 100 mg/ kg﹒d~- for two days. The positive control group was given chloramphenicol at the dose of 50 mg/kg﹒d~- 1h before killing the mice. The negative control group was given the same volume of saline solution. After the mice were killed by decapitation, The livers were removed and microsomes were isolated and then, the contents of CYP450 and b5 were measured by UV-spectrophotometry and compared with control group mice. 2. To evaluate the detoxification effect of TPs, the male mice were intragastricly pre-treated with TPs at the doses of 100, 200 and 400 mg/ kg﹒d~- for six days, The positive control group was given N-Broncholysin at the dose of 900 mg/kg﹒d~-. The negative control group was given the same volume of saline solution and then, all the mice were given paracetamol at the dose of 1000 mg/kg. The acute mortality was compared with control mice. 3. To examine the expression of CYP2E1 and CYP1A2, male mice were pre-treated with TPs (100, 200, and 400 mg/kg﹒d~-) for five days. The model group and the negative control group were given the same volume of saline solution. Then the mice were given paracetamol at the dose of 500 mg/kg 1 hour later after the last time TPs administration except the mice in negative control group. The livers were removed immediately and washed with cold saline solution .Then all specimens were fixed in formalin for histological examinations or snap-frozen in liquid nitrogen and stored at -80℃for protein and RNA extraction. CYP2E1 and CYP1A2 protein and mRNA expression levels in the liver were evaluated by western blotting, immunohistochemical staining and RT-PCR.
Results: The contents of CYP450 and b5 in the livers of mice in three TPs-treated groups were dose-dependently decreased compared with the negative control mice (P<0.01) after short time taking TPs. TPs treatment significantly improved hepatic lesions and led to a dramatic reduction of the mortality of paracetamol-treated mice. TPs treatment resulted in a significant reduction of the CYP2E1 and CYP1A2 expression at both protein and mRNA levels in a dose-dependent manner (P<0.01).
Conclusions:
1. TPs could suppress both CYP450 and b5 in a dose dependent manner after short time administration.
2. In the paracetamol induced mouse liver injury model, TPs demonstrated obvious hepato-protective effects dose-dependently which were shown by substantially lowering the mortality of mice and obviously improving hepatic lesions.
3. In the paracetamol induced mouse liver injury model, TPs could supressed CYP450 isoform CYP2E1 and CYP1A2 expression to defend paracetamol-induced liver damage. This result suggested TPs could reduced paracetamol’s metabolism and decrease the production of the hepatotoxic N-acetyl-p-benzoquinonimine by suppressing genetic transcription of CYP2E1 and CYP1A2. This might be one of the mechanisms to hepato-protective effects of TPs.
引文
1. Fujiki H. Green tea: Health benefits as cancer preventive for humans[J]. Chem Rec. 2005, 5(3): 119~132.
2.杜玉,娄红祥.表没食子儿茶素没食子酸酯药理作用研究进展.国外医药·植物药分册[J]. 2006, 21(6): 244~248.
3. Nassiani, Hajime, Ashida, et al. Blocking telomerase by dietary polyphenols is a major mechanismfor limiting the growth by human cancer cells in vitro and vivo[J]. Cancer Res. 2003, 63: 824~830.
4. Shi XY, et al. The antioxidation and mechanism of tea polyphenol[J]. Foreign Med Sci-Sec Pharm. 1998,25(4):196~198.
5. Lee SR, Im KJ, Suh SI, et al. Protective effect of green tea polyphenol (-)EGCG and other antioxidants on lipid peroxidation in gerbil brain homogene rates[J]. Phytotherapy Res. 2003, 17(1): 206~209.
6.李志光,谢文刚,张铭,等.茶多酚与细菌DNA相互作用的研究[J].茶叶科学. 2002,22(1): 62~65.
7.郑毅男,李想,韩立坤,等.乌龙茶减肥作用机制的研究[J].营养学报. 2001,23:342~345.
8. Yokozawa T, Nakagawa T, Kitani K. Antioxidative activity of green tea polyphenol in cholesterol-fed rats[J]. J Agric Fd Chem. 2002, 50(12): 3549~3552.
9.王蓓,邓红,苏宁,等.茶多酚对糖尿病大鼠活性氧表达的影响[J].东南大学学报(医学版). 2002, 21(1): 40~43.
10.陈立兵,葛卫红,林洁,等.细胞色素P450 mRNA表达研究进展[J].医学研究杂志. 2007, 36(7): 7~9.
11. Liu TT, Liang NS, Li Y, et al. Effects of long-term tea polyphenols consumption on hepatic microsomaldrug-metabolizing enzymes and liver function in Wistar rats[J]. World J Gastroenterol. 2003, 9(12): 2742~2744.
12. Pan H, Wu J, Zheng S. Inhibition of colorectal carcinoma induced by 1,2-dimethylhydrazine in mice with tea polyphenols. Zhonghua Yu Fang Yi Xue Za Zhi. 1995, 29(6): 356~359.
13. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951, 193: 265~275.
14.王润华.离群值检“Grubbs检验法”.见:周燕荣,王润华,王昌玲主编,医学检验统计学.科学技术文献出版社重庆分社. 1987, 366~369.
15. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation[J]. Pharmacol Ther. 2001, 92(2-3): 147.
16. Vernia S, Sanz-Gonzalez SM, Lopez-Garcia MP. Involvement of peroxynitrite on the early loss of p450 in short-term hepatocyte cultures[J]. Adv Exp Med Biol. 2001, 500: 209.
17.舒焱,周宏灏.细胞色素P450药物氧化代谢酶的遗传药理学进展[M].见:王永铭,苏定冯主编.药理学进展(2000).北京:科学出版社. 2000:19~36.
18. Lin J, Yao L, Lame M, et al. The increased emphasis of ADME properties in hit-to-lead drug discovery[J]. Acta Pharmacol Sin. 2006, 27(suppl): 226.
19.钟大放.药物代谢与药物动力学基础研究展望[J].辽宁药物与临床. 2000, 3(4): 145~148.
20. Periasamy Srinivasan, Subramaniyan Suchalatha, Pon Velayutham Anandh Babu, et al. Chemopreventive and therapeutic modulation of green tea polyphenols on drug metabolizing enzymes in 4-Nitroquinoline 1-oxide induced oral cancer[J]. Chem Biol Interact. 2008, 172(3): 224~234.
21. F. Catterall, N.J. McArdle, L. Mitchell, et al. Hepatic and intestinal cytochrome P450 and conjugase activities in rats treated with black tea theafulvins and theaflavins. Food and Chemical Toxicology. 2003, 41: 1141~1147.
22. Wang ZY, Das M, Bickers DR, et al. Interaction of epicatechins derived from green tea with rat hepatic cytochrome P-450[J]. Drug Metab Dispos. 1988, 16(1): 98~103.
23. Wijnen PA, Opden Buijsch RA, Drent M, et al. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms[J]. Aliment Pharmacol Ther. 2007, 26 Suppl 2: 211~219.
24. Oz HS, McClain CJ, Nagasawa HT, et al. Diverse antioxidants protect against acetaminophen hepatotoxicity[J]. J Biochem Mol Toxicol. 2004, 18(6): 361~368.
25. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years[J]. J Toxicol Clin Toxicol. 2002, 40: 3~20.
26. Kozer E, Koren G. Management of paracetamol overdose: current controversies[J]. Drug Saf. 2001, 24: 503~512.
27. Marnewick JL ,Joubert E ,Swart P , et al. Modulation of hepatic drug metabolizing enzymes and oxidative status by rooibos (Aspalathus linearis) and Honeybush (Cyclopia intermedia), green and black (Camellia sinensis) teas in rats[J]. J Agric Food Chem. 2003, 51: 8113~8119.
28. K.V.P. Chandra Mohan, R. Subapriya, Y. Hara, et al. Enhancement of Erythrocyte Antioxidants by Green and Black Tea Polyphenols During
7,12-Dimethylbenz[a]anthracene-Induced Hamster Buccal Pouch Carcinogenesis [J]. J Med Food. 2006, 9(3): 373~377.
29. Jiao HL, Ye P, Zhao BL. Protective Effects of Green Tea Polyphenols on Human HepG2 Cells Against Oxidative Damage of Fenofibrate[J]. Free Radical Biology & Medicine. 2003, 35(9): 1121~1128.
30. S. Mahaboob Khan. Protective effect of black tea extract on the levels of lipid peroxidation and antioxidant enzymes in liver of mice with pesticide-induced liver injury[J]. Cell Biochem Funct. 2006, 24: 327~332.
31.饶光宇,陈秀芬,于燕妮.茶多酚对小鼠实验性肝损伤的保护作用[J].中国中药杂志. 2001, 26(3): 191~193.
32.王宇光,高月,柴彪新,等.人参、藜芦合用对大鼠肝P450酶活性及mRNA表达的调控作用[J].中国中药杂志. 2004, 29(4): 366~370.
33.刘树民,张琳,李颖,等.黄药子与当归配伍对大鼠肝脏CYP1A2、CYP2E1基因mRNA表达的影响[J].中药药理与临床. 2006, 22(34): 97~98.
34. O. S. Sohn, A. Surace, E. S. Fiala, et al. Effects of green and black tea on hepatic xenobiotic metabolizing systems in the male rat[J]. Xenobiotica. 1994, 24: 119~127.
35. Chen LS, Flrdeliza Y. Bondoc, Lee MJ, et al. Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats[J]. Drug Metabolism and Disposition. 1996, 24(5): 529~533.
1. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997, 49: 403~449.
2. Coon MJ, Ding XX, Pernecky SJ, et al. Cytochrome P450: progress and predictions. FASEB J. 1992, 6(2): 669~673.
3. Porter TD, Coon MJ. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem. 1991, 266(21): 13469~13472.
4.黄林清,杨志勇.肝细胞色素P450与药物代谢的研究进展.中国药房. 2001, 12(6): 372~373.
5. Krishan DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin pharmacok. 1994, 24: 144~66.
6. Boccia S, De Lauretis A, Gianfagna F, et al. CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility: A meta-analysis of the literature. Carcinogenesis. 2007, 28(1): 101~106.
7. Kim YD, Eom SY, Ogawa M, et al. Ethanol-induced oxidative DNA damage and CYP2E1 expression in liver tissue of Aldh2 knockout mice. J Occup Health. 2007, 49(5): 363~369.
8. Cichoz-Lach H, Partycka J, Nesina I, et al. The influence of genetic polymorphism of CYP2E1 on the development of alcohol liver cirrhosis. Wiad Lek. 2006, 59(11~12): 757~761.
9. Oyama T, Sugio K, Uramoto H, et al. Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci. 2007, 12: 2299~2308.
10. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003, 192(1): 23~32.
11.刘移民,王翔朴.细胞色素氧化酶P450研究新进展.卫生毒理学杂志. 2000, 14(4): 243~246.
12.赵春梅,宓穗卿.肝微粒体细胞色素P450研究概况.中药新药与临床药理. 2002, 13(5): 334~337.
13. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001, 14(6): 611~650.
14. Wijnen PA, Opden Buijsch RA, Drent M, et al. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007, 26 Suppl 2: 211~219.
15. Wrighton SA ,vardonbradon M, Ring BJ. The human drug metabolizing cytochromes P450. J pharmacokinet Biopharm. 1996, 26: 461.
16.姚光弼.药物和毒物所致的肝病.临床肝脏病学.上海:上海科学技术出版社. 2004, 506~528.
17. Morgan ET, Li T, Cheng PY. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology. 2002, 181~182: 207~210.
18. Kocarek TA, Sheniy SD, Mercer-haines NA, et al. Use of dominant negative nuclear receptors to study xenobiotic-in-ducible gene expression in primary cultured hepatocytes. J Pharm acol ToxicolM ethods. 2002, 47(3): 177~187.
19. Mikamo E, Harada S, Nishikawa J, et al. Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor. Toxicol Appl Pharm acol. 2003, 193(1): 66~72.
20. Xie W, Barwick JL, Simon CM, et al. Reciprocal activation of xenobiotic response genes by nuclear receptor SXR/PXR and CAR. Genes Dev. 2000, 14 (23): 3014~3023.
21. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J. 2000, 347(2): 321~337.
22. Skupinska K, Misiewicz I, Kasprzycka-Guttman T. A comparison of the concentration-effect relationships of PAHs on CYP1A induction in HepG2 and Mcf7 cells. Arch Toxicol. 2007, 81(3): 183~200.
23. Simonsson US, Lindell M, Raffalli-Mathieu F, et al. In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin. Eur J Clin Invest. 2006, 36(9): 647~653.
24. Park,Y. Induction of cytochrome P450 enzymes that metabolize xenobiotics, In: Ortiz de onteliano Pr. Editor. Cytochrome P450: structure, metabolism and biochemistry, chapter 10. New York: Plenum Press.1995. 367~390.
25. Schuetz EG. Induction of cytochromes P450. Curr Drug Metab. 2001, 2: 139~147.
26. Liu ZW, Hu ZH, Cai YY.The combined effect of isoniazid and rifampicin on the activities of CYP4501A2 and CYP4503A4 in primary hepatocytes from healthy human adults. Zhonghua Jie He He Hu Xi Za Zhi. 2005, 28(11): 785~788.
27. Campbell IA. Toxicity of isoniazid and rifampicin combination. Thorax. 1995, 50: 814.
28.陈成伟.细胞色素P450遗传多态性意义.中毒与药物性肝病.上海:上海科学技术出版社. 2002, 313~327.
29. Haouzi D, LekehalM, Moreau A, et al. P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology. 2000, 32(2): 303~311.
30. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Current MolMed. 2003, 3(6): 483~490.
31. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury:mechanisms and test systems. Hepatology. 2001, 33(4): 1009~1013.
32. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatoisi and steatohepatitis. Ⅱ. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastointest Liuer Physiol. 2001, 281(5): G1135~G1139.
33. Vuppugalla R, Shah RB, Chimalakonda AP, et al . Micrisomal cytochrome P450 levels and activities of isolated rat livers perfused with albumin. Pharm Res. 2003, 20(1): 81~88.
34. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002, 40: 3~20.
35. Kozer E, Koren G. Management of paracetamol overdose: current controversies. Drug Saf. 2001, 24: 503~512.
36. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systems. Hepatology. 2001, 33(4): 1009~1013.
37.陈安树.细胞色素C在小鼠肝损伤及缺氧模型中的作用.沈阳药科大学学报. 2002, 19(1): 46~48.
38. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003, 33(2): 105~136.
39. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000, 84: 1275~1311.
40. Van Pelt FN, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Semin Liver Dis. 1995, 15: 283~300.
41. Desment VJ, Gerber M, Hoofnaagle JH. Classification of chronic hepatitis: diagnosis, grading and staging. J Hepat. 1994, 19 (6): 1513.
42. Strassburg CP, MannsMP. Autoantibodies and Autoantigens in autoimmune hepatitis. Semin Liver Dis. 2002, 22: 339~352.
43. Diamantis I, Boumpas DT. Autoimmune hepatitis:evolving concepts. Autoimmune Rev. 2004, 3(3): 207~214.
44. Muratori L, Lenzi M, Ma Y, et al. Heterogeneity of liver/kindney microsomal
29. Haouzi D, LekehalM, Moreau A, et al. P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology. 2000, 32(2): 303~311.
30. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Current MolMed. 2003, 3(6): 483~490.
31. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury:mechanisms and test systems. Hepatology. 2001, 33(4): 1009~1013.
32. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatoisi and steatohepatitis. Ⅱ. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastointest Liuer Physiol. 2001, 281(5): G1135~G1139.
33. Vuppugalla R, Shah RB, Chimalakonda AP, et al . Micrisomal cytochrome P450 levels and activities of isolated rat livers perfused with albumin. Pharm Res. 2003, 20(1): 81~88.
34. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002, 40: 3~20.
35. Kozer E, Koren G. Management of paracetamol overdose: current controversies. Drug Saf. 2001, 24: 503~512.
36. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systems. Hepatology. 2001, 33(4): 1009~1013.
37.陈安树.细胞色素C在小鼠肝损伤及缺氧模型中的作用.沈阳药科大学学报. 2002, 19(1): 46~48.
38. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003, 33(2): 105~136.
39. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000, 84: 1275~1311.
40. Van Pelt FN, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Semin Liver Dis. 1995, 15: 283~300.
41. Desment VJ, Gerber M, Hoofnaagle JH. Classification of chronic hepatitis: diagnosis, grading and staging. J Hepat. 1994, 19 (6): 1513.
42. Strassburg CP, MannsMP. Autoantibodies and Autoantigens in autoimmune hepatitis. Semin Liver Dis. 2002, 22: 339~352.
43. Diamantis I, Boumpas DT. Autoimmune hepatitis:evolving concepts. Autoimmune Rev. 2004, 3(3): 207~214.
44. Muratori L, Lenzi M, Ma Y, et al. Heterogeneity of liver/kindney microsomal
2.杜玉,娄红祥.表没食子儿茶素没食子酸酯药理作用研究进展.国外医药·植物药分册[J]. 2006, 21(6): 244~248.
3. Nassiani, Hajime, Ashida, et al. Blocking telomerase by dietary polyphenols is a major mechanismfor limiting the growth by human cancer cells in vitro and vivo[J]. Cancer Res. 2003, 63: 824~830.
4. Shi XY, et al. The antioxidation and mechanism of tea polyphenol[J]. Foreign Med Sci-Sec Pharm. 1998,25(4):196~198.
5. Lee SR, Im KJ, Suh SI, et al. Protective effect of green tea polyphenol (-)EGCG and other antioxidants on lipid peroxidation in gerbil brain homogene rates[J]. Phytotherapy Res. 2003, 17(1): 206~209.
6.李志光,谢文刚,张铭,等.茶多酚与细菌DNA相互作用的研究[J].茶叶科学. 2002,22(1): 62~65.
7.郑毅男,李想,韩立坤,等.乌龙茶减肥作用机制的研究[J].营养学报. 2001,23:342~345.
8. Yokozawa T, Nakagawa T, Kitani K. Antioxidative activity of green tea polyphenol in cholesterol-fed rats[J]. J Agric Fd Chem. 2002, 50(12): 3549~3552.
9.王蓓,邓红,苏宁,等.茶多酚对糖尿病大鼠活性氧表达的影响[J].东南大学学报(医学版). 2002, 21(1): 40~43.
10.陈立兵,葛卫红,林洁,等.细胞色素P450 mRNA表达研究进展[J].医学研究杂志. 2007, 36(7): 7~9.
11. Liu TT, Liang NS, Li Y, et al. Effects of long-term tea polyphenols consumption on hepatic microsomaldrug-metabolizing enzymes and liver function in Wistar rats[J]. World J Gastroenterol. 2003, 9(12): 2742~2744.
12. Pan H, Wu J, Zheng S. Inhibition of colorectal carcinoma induced by 1,2-dimethylhydrazine in mice with tea polyphenols. Zhonghua Yu Fang Yi Xue Za Zhi. 1995, 29(6): 356~359.
13. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951, 193: 265~275.
14.王润华.离群值检“Grubbs检验法”.见:周燕荣,王润华,王昌玲主编,医学检验统计学.科学技术文献出版社重庆分社. 1987, 366~369.
15. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation[J]. Pharmacol Ther. 2001, 92(2-3): 147.
16. Vernia S, Sanz-Gonzalez SM, Lopez-Garcia MP. Involvement of peroxynitrite on the early loss of p450 in short-term hepatocyte cultures[J]. Adv Exp Med Biol. 2001, 500: 209.
17.舒焱,周宏灏.细胞色素P450药物氧化代谢酶的遗传药理学进展[M].见:王永铭,苏定冯主编.药理学进展(2000).北京:科学出版社. 2000:19~36.
18. Lin J, Yao L, Lame M, et al. The increased emphasis of ADME properties in hit-to-lead drug discovery[J]. Acta Pharmacol Sin. 2006, 27(suppl): 226.
19.钟大放.药物代谢与药物动力学基础研究展望[J].辽宁药物与临床. 2000, 3(4): 145~148.
20. Periasamy Srinivasan, Subramaniyan Suchalatha, Pon Velayutham Anandh Babu, et al. Chemopreventive and therapeutic modulation of green tea polyphenols on drug metabolizing enzymes in 4-Nitroquinoline 1-oxide induced oral cancer[J]. Chem Biol Interact. 2008, 172(3): 224~234.
21. F. Catterall, N.J. McArdle, L. Mitchell, et al. Hepatic and intestinal cytochrome P450 and conjugase activities in rats treated with black tea theafulvins and theaflavins. Food and Chemical Toxicology. 2003, 41: 1141~1147.
22. Wang ZY, Das M, Bickers DR, et al. Interaction of epicatechins derived from green tea with rat hepatic cytochrome P-450[J]. Drug Metab Dispos. 1988, 16(1): 98~103.
23. Wijnen PA, Opden Buijsch RA, Drent M, et al. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms[J]. Aliment Pharmacol Ther. 2007, 26 Suppl 2: 211~219.
24. Oz HS, McClain CJ, Nagasawa HT, et al. Diverse antioxidants protect against acetaminophen hepatotoxicity[J]. J Biochem Mol Toxicol. 2004, 18(6): 361~368.
25. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years[J]. J Toxicol Clin Toxicol. 2002, 40: 3~20.
26. Kozer E, Koren G. Management of paracetamol overdose: current controversies[J]. Drug Saf. 2001, 24: 503~512.
27. Marnewick JL ,Joubert E ,Swart P , et al. Modulation of hepatic drug metabolizing enzymes and oxidative status by rooibos (Aspalathus linearis) and Honeybush (Cyclopia intermedia), green and black (Camellia sinensis) teas in rats[J]. J Agric Food Chem. 2003, 51: 8113~8119.
28. K.V.P. Chandra Mohan, R. Subapriya, Y. Hara, et al. Enhancement of Erythrocyte Antioxidants by Green and Black Tea Polyphenols During
7,12-Dimethylbenz[a]anthracene-Induced Hamster Buccal Pouch Carcinogenesis [J]. J Med Food. 2006, 9(3): 373~377.
29. Jiao HL, Ye P, Zhao BL. Protective Effects of Green Tea Polyphenols on Human HepG2 Cells Against Oxidative Damage of Fenofibrate[J]. Free Radical Biology & Medicine. 2003, 35(9): 1121~1128.
30. S. Mahaboob Khan. Protective effect of black tea extract on the levels of lipid peroxidation and antioxidant enzymes in liver of mice with pesticide-induced liver injury[J]. Cell Biochem Funct. 2006, 24: 327~332.
31.饶光宇,陈秀芬,于燕妮.茶多酚对小鼠实验性肝损伤的保护作用[J].中国中药杂志. 2001, 26(3): 191~193.
32.王宇光,高月,柴彪新,等.人参、藜芦合用对大鼠肝P450酶活性及mRNA表达的调控作用[J].中国中药杂志. 2004, 29(4): 366~370.
33.刘树民,张琳,李颖,等.黄药子与当归配伍对大鼠肝脏CYP1A2、CYP2E1基因mRNA表达的影响[J].中药药理与临床. 2006, 22(34): 97~98.
34. O. S. Sohn, A. Surace, E. S. Fiala, et al. Effects of green and black tea on hepatic xenobiotic metabolizing systems in the male rat[J]. Xenobiotica. 1994, 24: 119~127.
35. Chen LS, Flrdeliza Y. Bondoc, Lee MJ, et al. Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats[J]. Drug Metabolism and Disposition. 1996, 24(5): 529~533.
1. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997, 49: 403~449.
2. Coon MJ, Ding XX, Pernecky SJ, et al. Cytochrome P450: progress and predictions. FASEB J. 1992, 6(2): 669~673.
3. Porter TD, Coon MJ. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem. 1991, 266(21): 13469~13472.
4.黄林清,杨志勇.肝细胞色素P450与药物代谢的研究进展.中国药房. 2001, 12(6): 372~373.
5. Krishan DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin pharmacok. 1994, 24: 144~66.
6. Boccia S, De Lauretis A, Gianfagna F, et al. CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility: A meta-analysis of the literature. Carcinogenesis. 2007, 28(1): 101~106.
7. Kim YD, Eom SY, Ogawa M, et al. Ethanol-induced oxidative DNA damage and CYP2E1 expression in liver tissue of Aldh2 knockout mice. J Occup Health. 2007, 49(5): 363~369.
8. Cichoz-Lach H, Partycka J, Nesina I, et al. The influence of genetic polymorphism of CYP2E1 on the development of alcohol liver cirrhosis. Wiad Lek. 2006, 59(11~12): 757~761.
9. Oyama T, Sugio K, Uramoto H, et al. Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci. 2007, 12: 2299~2308.
10. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003, 192(1): 23~32.
11.刘移民,王翔朴.细胞色素氧化酶P450研究新进展.卫生毒理学杂志. 2000, 14(4): 243~246.
12.赵春梅,宓穗卿.肝微粒体细胞色素P450研究概况.中药新药与临床药理. 2002, 13(5): 334~337.
13. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001, 14(6): 611~650.
14. Wijnen PA, Opden Buijsch RA, Drent M, et al. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007, 26 Suppl 2: 211~219.
15. Wrighton SA ,vardonbradon M, Ring BJ. The human drug metabolizing cytochromes P450. J pharmacokinet Biopharm. 1996, 26: 461.
16.姚光弼.药物和毒物所致的肝病.临床肝脏病学.上海:上海科学技术出版社. 2004, 506~528.
17. Morgan ET, Li T, Cheng PY. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology. 2002, 181~182: 207~210.
18. Kocarek TA, Sheniy SD, Mercer-haines NA, et al. Use of dominant negative nuclear receptors to study xenobiotic-in-ducible gene expression in primary cultured hepatocytes. J Pharm acol ToxicolM ethods. 2002, 47(3): 177~187.
19. Mikamo E, Harada S, Nishikawa J, et al. Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor. Toxicol Appl Pharm acol. 2003, 193(1): 66~72.
20. Xie W, Barwick JL, Simon CM, et al. Reciprocal activation of xenobiotic response genes by nuclear receptor SXR/PXR and CAR. Genes Dev. 2000, 14 (23): 3014~3023.
21. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J. 2000, 347(2): 321~337.
22. Skupinska K, Misiewicz I, Kasprzycka-Guttman T. A comparison of the concentration-effect relationships of PAHs on CYP1A induction in HepG2 and Mcf7 cells. Arch Toxicol. 2007, 81(3): 183~200.
23. Simonsson US, Lindell M, Raffalli-Mathieu F, et al. In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin. Eur J Clin Invest. 2006, 36(9): 647~653.
24. Park,Y. Induction of cytochrome P450 enzymes that metabolize xenobiotics, In: Ortiz de onteliano Pr. Editor. Cytochrome P450: structure, metabolism and biochemistry, chapter 10. New York: Plenum Press.1995. 367~390.
25. Schuetz EG. Induction of cytochromes P450. Curr Drug Metab. 2001, 2: 139~147.
26. Liu ZW, Hu ZH, Cai YY.The combined effect of isoniazid and rifampicin on the activities of CYP4501A2 and CYP4503A4 in primary hepatocytes from healthy human adults. Zhonghua Jie He He Hu Xi Za Zhi. 2005, 28(11): 785~788.
27. Campbell IA. Toxicity of isoniazid and rifampicin combination. Thorax. 1995, 50: 814.
28.陈成伟.细胞色素P450遗传多态性意义.中毒与药物性肝病.上海:上海科学技术出版社. 2002, 313~327.
29. Haouzi D, LekehalM, Moreau A, et al. P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology. 2000, 32(2): 303~311.
30. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Current MolMed. 2003, 3(6): 483~490.
31. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury:mechanisms and test systems. Hepatology. 2001, 33(4): 1009~1013.
32. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatoisi and steatohepatitis. Ⅱ. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastointest Liuer Physiol. 2001, 281(5): G1135~G1139.
33. Vuppugalla R, Shah RB, Chimalakonda AP, et al . Micrisomal cytochrome P450 levels and activities of isolated rat livers perfused with albumin. Pharm Res. 2003, 20(1): 81~88.
34. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002, 40: 3~20.
35. Kozer E, Koren G. Management of paracetamol overdose: current controversies. Drug Saf. 2001, 24: 503~512.
36. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systems. Hepatology. 2001, 33(4): 1009~1013.
37.陈安树.细胞色素C在小鼠肝损伤及缺氧模型中的作用.沈阳药科大学学报. 2002, 19(1): 46~48.
38. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003, 33(2): 105~136.
39. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000, 84: 1275~1311.
40. Van Pelt FN, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Semin Liver Dis. 1995, 15: 283~300.
41. Desment VJ, Gerber M, Hoofnaagle JH. Classification of chronic hepatitis: diagnosis, grading and staging. J Hepat. 1994, 19 (6): 1513.
42. Strassburg CP, MannsMP. Autoantibodies and Autoantigens in autoimmune hepatitis. Semin Liver Dis. 2002, 22: 339~352.
43. Diamantis I, Boumpas DT. Autoimmune hepatitis:evolving concepts. Autoimmune Rev. 2004, 3(3): 207~214.
44. Muratori L, Lenzi M, Ma Y, et al. Heterogeneity of liver/kindney microsomal
29. Haouzi D, LekehalM, Moreau A, et al. P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology. 2000, 32(2): 303~311.
30. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Current MolMed. 2003, 3(6): 483~490.
31. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury:mechanisms and test systems. Hepatology. 2001, 33(4): 1009~1013.
32. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatoisi and steatohepatitis. Ⅱ. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastointest Liuer Physiol. 2001, 281(5): G1135~G1139.
33. Vuppugalla R, Shah RB, Chimalakonda AP, et al . Micrisomal cytochrome P450 levels and activities of isolated rat livers perfused with albumin. Pharm Res. 2003, 20(1): 81~88.
34. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002, 40: 3~20.
35. Kozer E, Koren G. Management of paracetamol overdose: current controversies. Drug Saf. 2001, 24: 503~512.
36. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systems. Hepatology. 2001, 33(4): 1009~1013.
37.陈安树.细胞色素C在小鼠肝损伤及缺氧模型中的作用.沈阳药科大学学报. 2002, 19(1): 46~48.
38. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003, 33(2): 105~136.
39. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000, 84: 1275~1311.
40. Van Pelt FN, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Semin Liver Dis. 1995, 15: 283~300.
41. Desment VJ, Gerber M, Hoofnaagle JH. Classification of chronic hepatitis: diagnosis, grading and staging. J Hepat. 1994, 19 (6): 1513.
42. Strassburg CP, MannsMP. Autoantibodies and Autoantigens in autoimmune hepatitis. Semin Liver Dis. 2002, 22: 339~352.
43. Diamantis I, Boumpas DT. Autoimmune hepatitis:evolving concepts. Autoimmune Rev. 2004, 3(3): 207~214.
44. Muratori L, Lenzi M, Ma Y, et al. Heterogeneity of liver/kindney microsomal
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |